Sun Pharma is recalling 54,960 bottles of Mesalamine Extended-Release Capsules, an anti-inflammatory medicine used to treat a type of bowel disease known as ulcerative colitis
It’s not as if domestic manufacturing has suddenly become sloppy. A closer look will reveal the strides made by Indian pharma firms as they attempt to break into the complex drugs space, which attracts higher scrutiny.
Sun Pharma stock has gained 5.88 per cent in a year and fallen 2.29 percent in 2023. A total of 0.52 lakh shares of the firm changed hands amounting to a turnover of Rs 5.08 crore on BSE.
"US FDA has directed the Company to take certain corrective actions at the Mohali facility before releasing further final product batches into the US," the company said.